| Name | Title | Contact Details |
|---|
We are a precision medicines company looking to eliminate the “all comer” approach that is seen with today`s treatments for people with autoimmune disease. We are leveraging a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.
Eurofins is a Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BMG Labtech is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.
Rheonix, Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. As scientific knowledge evolves, so does the need for new diagnostic technology to simplify processes and enhance innovation. Rheonix, through experienced leadership and creative vision, has developed the Encompass platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy to use and economical format on the Rheonix CARD® cartridge. With both the Rheonix CARD and Encompass family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in-between.